You are here

Positive Phase IV Data Reported for Nuedexta (Dextromethorphan/ Quinidine) in Patients With Alzheimer’s Disease/Dementia

Treatment reduces symptoms of pseudobulbar affect

Interim data from a new phase IV study has shown that treatment with Nuedexta (Avanir Pharmaceuticals) substantially reduced the symptoms of pseudobulbar affect (PBA) in patients with Alzheimer’s disease (AD)/dementia. PBA is a neurologic condition characterized by sudden and uncontrolled outbursts of laughing and/or crying in patients with neurologic disease or injury.

A standard quality-of-life (QOL) measure also showed clear improvement during the 3-month treatment period.

The findings were presented July 16 at the Alzheimer’s Association International Conference, held in Copenhagen, Denmark.

Nuedexta is a combination of dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. Nuedexta acts on sigma-1 and N-methyl-D-aspartate (NMDA) receptors in the brain, although the mechanism by which it exerts its therapeutic effects in patients with PBA is unknown.

The PRISM II trial was an open-label, 12-week study involving approximately 450 patients with AD/dementia. Eligible subjects were 18 years of age or older with a clinical diagnosis of PBA and a baseline score of 13 or greater on the Center for Neurologic Study–Lability Scale (CNS-LS).

The study assessed the efficacy and safety of Nuedexta in treating PBA in patients with AD/dementia, stroke, or traumatic brain injury. At the time of the interim analysis, 68 patients with AD/dementia had evaluable efficacy data and 96 patients had evaluable safety after at least 30 days of treatment. The study endpoints included a PBA symptom rating (CNS-LS score of 7 [no symptoms] to 35 [maximum symptoms]); the number of weekly PBA episodes; the Mini-Mental State Examination (MMSE) score; QOL improvements (0 = no impairment; 10 = maximum impairment); and Clinician and Patient Global Impression of Change (CGI-C/PGI-C).

At baseline, the patients had a mean CNS-LS score of 20.2 and a median of 29 PBA episodes per week. At the end of the study, the mean CNS-LS improved to 12.8 (P

Mean QOL scores improved from 6.1 at baseline to 2.8 at endpoint (P

Adverse events (AE) were reported by 35 (36.5%) patients (6.3% treatment-related). The most common AEs were headache (9.4%), urinary tract infection (5.2%), and diarrhea (4.2%). Eleven patients had serious AEs (only one deemed treatment-related). Thirteen patients discontinued treatment because of AEs.

Source: Avanir Pharmaceuticals; July 16, 2014.

Recent Headlines

More research is needed to confirm the finding
Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention
Rationing, canceled treatments, and fearful patients
Your heart will thank you